Figure 1.

Study design and schematic overview of the treatment in the cell line-derived xenograft-humanized mouse model. CD34-positive hematopoietic stem cells derived from human umbilical cord blood were transplanted into mice, and osimertinib-resistant lung cancer cells (PC-9/OR) were implanted in the right intercostal of 12 weeks posthumanized NSG mice. The developed CDX-humanized mice were divided into four groups based on treatment (no treatment (n=2); cetuximab only (n=3); NK cells only (n=4); cetuximab with NK cells (n=4)) and treated weekly for 5 weeks (NK cells, 1×10⁷ cells/dose; cetuximab, 0.4 mg/kg/dose). CDX, cell line-derived xenograft; OR, osimertinib resistance; NK cell, natural killer cell.